arteriosclerosis atherosclerosis
Conditions
Interventions
None listed
Sponsors
Radboud University Nijmegen Medical Centre
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Diagnosis of Familial Combined Hyperlipidemia (FCH) in the patient cohort and relatives. In population-based cohort: age at time of inclusion in NIMA1: 50-70 years, part of Nijmegen Biomedical Study.
Exclusion criteria
Exclusion criteria: Age under 18 in FCH cohort.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary objectives: 1. To unravel the impact of time and time of exposure to different CV risk factors on the development and progression of (subclinical)atherosclerosis, as measured by repeated NIMA, and CVD, as measured by clinical endpoints in both the general population and families with FCH. 2. To develop an evidence-based protocol for NIMA to improve cardiovascular risk stratification for the individual patient in clinical practice. 3. To determine which traditional and new clinical, biochemical and genetic CV risk factors are the main determinants of each of the NIMA (FMD, ABI at rest and after exercise, PWV, PWA parameters, IMT and presence and thickness of plaques in the carotid arteries) | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary objectives: - Data on the short-term variability in NIMA will enable us to better determine the predictive value of NIMA. - To unravel differences in the development of subclinical atherosclerosis and CV events between men and women. - Identification of the combination of NIMA that will improve CV risk stratification in a low and a high-risk population in a cost-effective way, allowing earlier and more effective (new) preventive therapy in both the general population and families with FCH. - To evaluate the power of baseline versus repeated NIMA in CVD risk prediction, over and beyond CV risk factors in both the general population and families with FCH. | — |
Countries
Netherlands
Outcome results
None listed